Federal officials approved a new pain pill designed to eliminate the risks of addiction and overdose associated with opioid ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX stock over the recent years has been far from consistent, and has largely ...

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to ...

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain and reduce the effects of the ...

Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...